Tuberculosis Drug Discovery and Development 2019
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main c...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2020 |
Language: | English |
Physical Description: | 1 electronic resource (296 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546196904498 |
---|---|
ctrlnum |
(CKB)5400000000045143 (oapen)https://directory.doabooks.org/handle/20.500.12854/69332 (EXLCZ)995400000000045143 |
collection |
bib_alma |
record_format |
marc |
spelling |
Riccardi, Giovanna edt Tuberculosis Drug Discovery and Development 2019 Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (296 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue. English Research & information: general bicssc Biology, life sciences bicssc mycobacteria tuberculosis multi-drug resistance drug discovery promiscuous targets Mycobacterium tuberculosis rifampin isoniazid mechanisms of resistance mutations granulomas caseum cell envelope dormancy delpazolid macozinone DprE1 inhibitor clinical studies discovery mode of action drug resistance toxicity target energy metabolism electron transport chain oxidative phosphorylation bedaquiline Q203 MID3 pharmacokinetics pharmacodynamics drug-drug interactions in vitro in vivo drug development tuberculosis treatment biomarkers drug combination clinical trial BCG tuberculosis vaccines TBVI EDCTP IAVI CTVD host-directed therapy anti-virulence compounds TB post-treatment sequelae surgery pulmonary rehabilitation Carlo Forlanini artificial pneumothorax structure-based drug design target-based drug design PknB PknG DNA gyrase antibiotic mycobacterium genomics transcriptomics proteomics metabolomics lipidomics target identification mechanism of action antimicrobial drug resistance (AMR) target-based screening phenotypic screening antituberculosis agents antimycobacterial anti-TB drug pipeline privileged targets lead generation 3-03943-236-2 3-03943-237-0 Sala, Claudia edt Riccardi, Giovanna oth Sala, Claudia oth |
language |
English |
format |
eBook |
author2 |
Sala, Claudia Riccardi, Giovanna Sala, Claudia |
author_facet |
Sala, Claudia Riccardi, Giovanna Sala, Claudia |
author2_variant |
g r gr c s cs |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Tuberculosis Drug Discovery and Development 2019 |
spellingShingle |
Tuberculosis Drug Discovery and Development 2019 |
title_full |
Tuberculosis Drug Discovery and Development 2019 |
title_fullStr |
Tuberculosis Drug Discovery and Development 2019 |
title_full_unstemmed |
Tuberculosis Drug Discovery and Development 2019 |
title_auth |
Tuberculosis Drug Discovery and Development 2019 |
title_new |
Tuberculosis Drug Discovery and Development 2019 |
title_sort |
tuberculosis drug discovery and development 2019 |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2020 |
physical |
1 electronic resource (296 p.) |
isbn |
3-03943-236-2 3-03943-237-0 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT riccardigiovanna tuberculosisdrugdiscoveryanddevelopment2019 AT salaclaudia tuberculosisdrugdiscoveryanddevelopment2019 |
status_str |
n |
ids_txt_mv |
(CKB)5400000000045143 (oapen)https://directory.doabooks.org/handle/20.500.12854/69332 (EXLCZ)995400000000045143 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Tuberculosis Drug Discovery and Development 2019 |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796652236244254722 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04768nam-a2201225z--4500</leader><controlfield tag="001">993546196904498</controlfield><controlfield tag="005">20231214132946.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045143</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69332</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045143</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Riccardi, Giovanna</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Tuberculosis Drug Discovery and Development 2019</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (296 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research & information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biology, life sciences</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mycobacteria</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tuberculosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multi-drug resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug discovery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">promiscuous targets</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Mycobacterium tuberculosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rifampin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">isoniazid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mechanisms of resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">granulomas</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">caseum</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell envelope</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dormancy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">delpazolid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">macozinone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DprE1 inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical studies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">discovery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mode of action</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">toxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">energy metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">electron transport chain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oxidative phosphorylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bedaquiline</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Q203</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MID3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacokinetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacodynamics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug-drug interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vitro</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vivo</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug development</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tuberculosis treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug combination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BCG</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tuberculosis vaccines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TBVI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EDCTP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IAVI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CTVD</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">host-directed therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-virulence compounds</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TB</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">post-treatment sequelae</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">surgery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pulmonary rehabilitation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Carlo Forlanini</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">artificial pneumothorax</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">structure-based drug design</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target-based drug design</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PknB</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PknG</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA gyrase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mycobacterium</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">proteomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lipidomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target identification</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mechanism of action</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimicrobial drug resistance (AMR)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target-based screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phenotypic screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antituberculosis agents</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimycobacterial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-TB drug pipeline</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">privileged targets</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lead generation</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-236-2</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-237-0</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sala, Claudia</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Riccardi, Giovanna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sala, Claudia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:37:57 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338121560004498&Force_direct=true</subfield><subfield code="Z">5338121560004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338121560004498</subfield></datafield></record></collection> |